Advanced search
Publication Cover
mAbs Volume 4, 2012 - Issue 1
Submit an article Journal homepage
1,559
Views
13
CrossRef citations to date
0
Altmetric
Report

Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects

Bo Zhou These authors contributed equally to this work.; International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Birong Lin These authors contributed equally to this work.; National Engineering Research Center of Antibody Medicine; Shanghai, China
,
Jing Li These authors contributed equally to this work.; International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Weizhu Qian International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Sheng Hou International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Dapeng Zhang International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Geng Kou International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Bohua Li International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, China
,
Hao Wang International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, ChinaCorrespondence[email protected] [email protected] [email protected]
,
Yongchuan Chen Southwest Hospital; The Third Military Medical University; Chongqing, ChinaCorrespondence[email protected] [email protected] [email protected]
&
Yajun Guo International Cancer Research Institute; The Second Military Medical University; Shanghai, China; PLA General Hospital Cancer Center; PLA Postgraduate School of Medicine; Beijing, ChinaCorrespondence[email protected] [email protected] [email protected]
 show all
Pages 110-119 | Received 24 Aug 2011, Accepted 08 Oct 2011, Published online: 01 Jan 2012

References

  • Ishizaka T, Ishizaka K. Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984; 34:188 - 235; PMID: 6199797
  • Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623 - 2632; PMID: 8360482
  • Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110 - 121; PMID: 9257795; http://dx.doi.org/10.1016/S0091-6749(97)70202-1
  • Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107 - 113; PMID: 19130931; http://dx.doi.org/10.1016/j.jaci.2008.09.050
  • Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19:491 - 498; PMID: 14594521; http://dx.doi.org/10.1185/030079903125002171
  • Genentech, Inc. Xolair® (omalizumab for subcutaneous use) label 29 Sep 2011 Available at www.accessdata.fda.gov/drugsatfda_docs/label/2007/103976s5102lbl.pdf
  • Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673 - 680; PMID: 5443170; http://dx.doi.org/10.1172/JCI106279
  • Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310 - 312; PMID: 21478841; http://dx.doi.org/10.1038/nbt.1839
  • Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21:13 - 16; PMID: 16959789; http://dx.doi.org/10.1093/ndt/gfl475
  • Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45:792 - 801; PMID: 15951469; http://dx.doi.org/10.1177/0091270005277075
  • Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006; 23:1275 - 1284; PMID: 16715358; http://dx.doi.org/10.1007/s11095-006-0205-x
  • Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62:779 - 786; PMID: 18205003; http://dx.doi.org/10.1007/s00280-007-0664-8
  • Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25:1700 - 1721; PMID: 12860493; http://dx.doi.org/10.1016/S0149-2918(03)80164-9
  • Froehlich J, Schoenhoff M, Tremblay T, Ruppel J, Jardieu P. Initial human study with a humanized recombinant anti-IgE monoclonal antibody: safety, tolerance and pharmacokinetic (PK)/dynamic profile. Clin Pharmacol Ther 1995; 57:162
  • Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010; 28:509 - 516; PMID: 20691488; http://dx.doi.org/10.1016/j.tibtech.2010.07.001
  • Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know—a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23:3731 - 3737; PMID: 18802209; http://dx.doi.org/10.1093/ndt/gfn519
  • Li J, Li X, Tan M, Lin B, Hou S, Qian W, et al. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study. mAbs 2009; 1:49 - 55; PMID: 20046574; http://dx.doi.org/10.4161/mabs.1.1.7399
  • European Medicines Agency. Valtropin: scientific discussion 2007 29 Sep 2011 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000602/WC500047158.pdf
  • Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548 - 561; PMID: 17096680; http://dx.doi.org/10.1111/j.1365-2125.2006.02803.x

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.